School of Gastrointestinal Oncology | Conference

Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

April 14th 2022

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.

Patient Goals and Characteristics Play an Outsized Role in Determining First-Line Treatment for mCRC

April 6th 2022

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC

April 1st 2022

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.

Marshall Highlights the Importance of Distinct Approaches to GI Cancers

April 1st 2022

Distinctions in histology, molecular profiles, and tumor location have set diverging course of care for the treatment of patients with gastrointestinal cancers.

Dr. Marshall on Utilizing Precision Medicine in Bile Duct Cancer

March 31st 2022

John L. Marshall, MD, discusses potential next steps with research in bile duct cancer.

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Racial Disparities Persist in GI Cancers and Beyond

March 24th 2021

Racial disparities affecting all aspects of patient care are a major issue across cancer types, including for patients with gastrointestinal cancers.

Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies

March 23rd 2021

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

Dr. Choti on Challenging Treatment Decisions in NETs

March 23rd 2021

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

The Future of Biliary Tract Treatment Lies in Molecular Profiling

March 22nd 2021

Although the genetic makeup of biliary tract cancer is rich, only recently has the field been able to show the benefit of treating patients with effective targeted agents, such as pemigatinib and ivosidenib in the advanced setting.

Debate Continues on Optimal Neoadjuvant Regimen in Resectable Pancreatic Cancer

April 2nd 2020

Michael A. Choti, MD, MBA, FACS, discusses the role of radiation therapy in neoadjuvant therapy for resectable pancreatic cancer, the many benefits of neoadjuvant therapy over up-front surgery, and minimally invasive surgical procedures that are coming to the forefront in this disease.

Novel Approaches to Build on Checkpoint Inhibition in GI Cancers

April 1st 2020

Despite some success stories, most gastrointestinal cancers do not respond to single-agent, or even double-agent, immune checkpoint inhibition, Neeha Zaidi, MD, said in a presentation during the 5th Annual School of Gastrointestinal Oncology™ (SOGO®) conference.

Targeted Agents Show Promise in Cholangiocarcinoma

March 31st 2020

Cholangiocarcinoma is both rare and aggressive, and the current systemic standard of care, gemcitabine plus cisplatin, produces only modest results.

Management, Etiology of Younger Patients With CRC Require Deeper Understanding

March 31st 2020

The etiology and overall management of patients with early-onset colorectal cancer needs to be better understood and personalized, respectively, explained Andrea Cercek, MD, in a presentation during the 5th Annual School of Gastrointestinal Oncology™.

Dr. Shah on the Role of Immunotherapy in Gastroesophageal Cancer

March 21st 2020

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Dr. Choti on the Benefits of Neoadjuvant Chemotherapy in Pancreatic Cancer

March 21st 2020

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

Dr. Marshall on Challenges in CRC Treatment

March 21st 2020

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer

April 26th 2016

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Novel Agents on Horizon for Advanced HCC

April 26th 2016

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.